Smy2p Participates in COPII Vesicle Formation Through the Interaction with Sec23p/Sec24p Subcomplex

Hironori Higashio1,2, Ken Sato1,3 and Akihiko Nakano1,4,*

1Molecular Membrane Biology Laboratory, RIKEN Discovery Research Institute, 2-1 Hirosawa, Wako, Saitama 351-0198, Japan
2Current address: Department of Biochemistry, Institute of Health Biosciences, The University of Tokushima Graduate School, 3-18-15 Kuramoto-cho, Tokushima, Tokushima 770-8503, Japan
3Current address: Department of Life Sciences, Graduate School of Arts and Sciences, University of Tokyo, 3-8-1 Komaba, Meguro-ku, Tokyo 153-8902, Japan
4Department of Biological Sciences, Graduate School of Science, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan
*Corresponding author: Akihiko Nakano, nakano@riken.jp

Key words: coat protein complex II, endoplasmic reticulum, multicopy suppressor, Saccharomyces cerevisiae, SEC24, vesicle formation

Received 5 July 2007, revised and accepted for publication 25 October 2007, uncorrected manuscript published online 28 October 2007, published online 27 November 2007

The coat protein complex II (COPII) is essential for vesicle formation from the endoplasmic reticulum (ER) and is composed of two heterodimeric subcomplexes, Sec23p/Sec24p and Sec13p/Sec31p, and the small guanosine triphosphatase Sar1p. In an effort to identify novel factors that may participate in COPII vesicle formation, we isolated SMY2, a yeast gene encoding a protein of unknown function, as a multicopy suppressor of the temperature-sensitive sec24-20 mutant. We found that even a low-copy expression of SMY2 was sufficient for the suppression of the sec24-20 phenotypes, and the chromosomal deletion of SMY2 led to a severe growth defect in the sec24-20 background. In addition, SMY2 exhibited genetic interactions with several other genes involved in the ER-to-Golgi transport. Subcellular fractionation analysis showed that Smy2p was a peripheral membrane protein fractionating together with COPII components. However, Smy2p was not loaded onto COPII vesicles generated in vitro. Interestingly, coimmunoprecipitation between Smy2p and the Sec23p/Sec24p subcomplex was specifically observed in sec23-1 and sec24-20 backgrounds, suggesting that this interaction was a prerequisite for the suppression of the sec24-20 phenotypes by overexpression of SMY2. We propose that Smy2p is located on the surface of the ER and facilitates COPII vesicle formation through the interaction with Sec23p/Sec24p subcomplex.

In eukaryotic cells, protein transport along the secretory pathway is mediated by transport vesicles, which emerge from a donor organelle and fuse with an appropriate target organelle. Newly synthesized secretory proteins are correctly folded in the endoplasmic reticulum (ER), which is the starting point of the secretory pathway, and then exported to the Golgi apparatus by coat protein complex II (COPII)-coated vesicles (1). COPII coat is essential for vesicle formation from the ER membrane and is composed of the small guanosine triphosphatase (GTPase) Sar1p (2) and heterodimeric subcomplexes, Sec23p/Sec24p and Sec13p/Sec31p (3). The vesicle formation starts with the conversion of inactive Sar1p-GDP to active Sar1p-GTP by Sec12p, the guanine-nucleotide exchange factor (GEF) for Sar1p, localized on the ER membrane (4,5). Sar1p-GTP binds to the ER membrane and then sequentially recruits Sec23p/Sec24p and Sec13p/Sec31p to form a bud that is finally pinched off as a COPII vesicle (3). After formation, COPII vesicles lose their coats, and the resulting naked vesicles undergo tethering, docking and fusion to the Golgi membrane (6). Coat disassembly requires GTP hydrolysis of Sar1p, which is stimulated by Sec23p, the GTPase activating protein (GAP) for Sar1p (7,8).

In addition to COPII vesicle formation, packaging of cargo molecules into vesicles is driven by the Sar1p–Sec23p/Sec24p prebudding complexes (9–11). Recent studies demonstrate that Sec24p contains several cargo-binding sites on its membrane-proximal surface and acts as the coat for cargo selection (12–14). The Sec24p ‘A-site’ recognizes YxoxNPF motif on the soluble n-ethylmaleimidesensitive fusion protein attachment protein receptor (SNARE), Sed5p, and the ‘B-site’ binds multiple motifs: Lxx(L/M)E on the SNAREs, Sed5p and Bet1p, and (D/E)x(D/E) on the Golgi protein Sys1p (13,14). The ‘C-site’ binds the SNARE Sec22p by recognizing its conformational epitope (13–15). Moreover, the existence of Sec24p subtypes in both yeast and mammals expands the cargo multiplicity captured by COPII coat (16–21). For example,
Higashio et al.

Saccharomyces cerevisiae has two nonessential Sec24p homologues, Sfb2p (Iss1p) (56% identity) and Sfb3p (Lst1p) (23% identity), both of which can form a complex with Sec23p (16–19). Sfb3p is specialized for efficient packaging of the plasma membrane proton adenosine triphosphatase Pma1p into COPII vesicles (22), and chromosomal disruption of SFB3 results in the pH-sensitive growth defect because of the arrest of Pma1p in the ER (19). In contrast, Sfb2p appears to be a functionally redundant Sec24p homologue because its overproduction not only suppresses the temperature-sensitive phenotypes of the sec24 mutants but also replaces the essential gene SEC24 (16–18).

Reconstitution studies have demonstrated that COPII components themselves are minimal requirements to drive vesicle formation from chemically defined liposomes (23–25). Although dispensable for the reconstitution, there are additional proteins involved in COPII vesicle formation in vivo: Sec16p, Sed4p and the Yip1p–Yif1p–Yos1p complex. Sec16p is a large, hydrophobic protein that associates peripherally with the ER membrane and can bind with Sec23p, Sec24p and Sec31p through its distinct domains (26–28). Sec16p is shown to bind to liposomes and facilitates the recruitment of COPII components and the following vesicle formation without regulating Sar1p-GTP hydrolysis (29), indicating that Sec16p is a scaffold for the assembly of COPII coats. In yeast Pichia pastoris and mammalian cells, Sec16p localizes to discrete subdomains of the ER termed transitional ER or ER exit sites and is involved in their organization as well as COPII vesicle formation (30,31). Sed4p is an integral membrane protein localized on the ER, whose cytoplasmic domain shares 45% identity with that of Sec12p (32). SED4 exhibits genetic interactions with SEC12, SEC16 and SAR1 (33,34), and chromosomal disruption of SED4 results in a decreased rate of ER-to-Golgi transport (33), suggesting the involvement of Sed4p in COPII vesicle formation. Finally, Yip1p is an integral membrane protein previously found to interact with several Rab GTPases including Ypt1p (35,36) and forms a heterodimeric complex with its homologue Yif1p (37). From the observations that YIP1 exhibits genetic interactions with SEC12, SEC13 and SEC23 and that ER membranes from the temperature-sensitive yip1 allele show reduced COPII vesicle formation in vitro, Yip1p is likely implicated in COPII vesicle formation (38). Moreover, the Yip1p–Yif1p complex forms a ternary complex with another integral membrane protein Yos1p, whose defect also shows reduced COPII vesicle formation in vitro (39). Like Sec16p, Yip1A, a mammalian homologue of Yip1p, localizes to ER exit sites (40). Thus, it seems likely that the process by which COPII vesicles are formed is more complex in vivo than in vitro, and these observations prompt us to investigate other unknown proteins involved in COPII vesicle formation.

In this report, we characterized SMY2, a high-copy suppressor of the temperature-sensitive sec24-20 mutant. While Sec24-20p can form a complex with Sec23p, the sec24-20 mutation results in the severe blockage in ER-to-Golgi transport and the significant accumulation of the ER membrane without obvious vesicle accumulation at the restrictive temperature, strongly suggesting the defects in COPII vesicle formation (17). Our genetic and biochemical evidence suggests the involvement of Smy2p in COPII vesicle formation.

Results

SMY2 is a novel suppressor of the sec24-20 mutant

We screened a YEp13 (LEU2, 2μ)-based yeast genomic DNA library (41) for high-copy suppressors of the temperature-sensitive sec24-20 mutant and repeatedly obtained plasmids that harbored a genomic fragment containing six complete open reading frames (ORFs), YBR171w to YBR176w. After subcloning, YBR172c was found to be responsible for the suppression. This ORF remained to be characterized; however, it had already been named SMY2 (suppressor of myosin 2) because of its previous identification as a high-copy suppressor of the temperature-sensitive myosin V mutant myo2-66 (42). Thus, we hereafter call this ORF SMY2.

As shown in Figure 1A, the high-copy (2μ) and low-copy (CEN) plasmids containing SMY2 suppressed the growth defect of sec24-20 cells to the same extent at the restrictive temperature of 33°C. To directly observe whether the overexpression of SMY2 rescues the ER-to-Golgi transport defect of sec24-20 cells, we performed pulse–chase analysis of a vacuolar protein carboxypeptidase Y (CPY) and a glycosylphosphatidylinositol-anchored plasma membrane protein Gas1p (Figure 1B). Newly synthesized CPY is detected as the 125-kDa mature form (m) in the Golgi and then proteolytically processed to the mature form (m; 61 kDa) in the vacuole (43). Similarly, Gas1p is detected as the 105-kDa precursor form (p) in the ER, further modified to the p2 form (69 kDa) in the Golgi and then delivered to the plasma membrane (44,45). As shown in Figure 1B, sec24-20 cells exhibited severe maturation defects of both proteins and accumulated their ER forms (p1 of CPY and p of Gas1p) at the restrictive temperature of 33°C. These defects were partially suppressed by either high-copy (2μ) or low-copy (CEN) SMY2 plasmid. These results indicate that even the low-copy (CEN) expression of SMY2 is sufficient for the suppression of temperature-sensitive sec24-20 phenotypes. As far as we examined, the overexpression of SMY2 affected neither growth nor ER-to-Golgi transport in wild-type cells (data not shown).

We previously showed that overexpression of SFB2 (ISS1) suppresses the sec24-20 phenotypes (17). To address the relationship between SMY2 and SFB2, we examined whether overexpression of SMY2 suppresses the temperature-sensitive growth defect of the sec24-20
mutant that is lacking SFB2 (sec24-20Δsfb2). Chromosomal disruption of SFB2 did not exacerbate the temperature-sensitive growth defect of the sec24-20 cells (data not shown). Both the high-copy (2μ) and the low-copy (CEN) expression of SMY2 suppressed the growth defect of sec24-20Δsfb2 cells at the restrictive temperature of 33°C (Figure 1C), indicating that endogenous Sfb2p is not involved in the suppression by overexpression of SMY2. We therefore concluded that SMY2 is a novel suppressor of the sec24-20 mutant.

**Smy2p and its homologue Ypl105cp**

SMY2 encodes a 790 amino acid residue protein with a predicted molecular mass of 87 kDa. As shown in Figure 2A, Smy2p is predicted to contain a GYF domain, a proline-rich sequence binding module (46,47), and a coiled-coil region by the SMART program (48,49). Its hydropathy profile indicates that Smy2p is a hydrophilic protein containing neither signal sequence nor transmembrane domain (Figure 2B). The Saccharomyces genome also contains an uncharacterized ORF YPL105c encoding an 849 amino acid residue protein with 30% overall identity to Smy2p (Figure 2A) (48–50). Besides the GYF and coiled-coil domains, the region corresponding to carboxy-terminal 100 amino acids is highly conserved between Smy2p and Ypl105cp. However, overexpression of YPL105c failed to suppress the temperature-sensitive growth defect of sec24-20 cells (Figure 2C). To determine whether SMY2 and YPL105c are required for growth, we constructed a diploid strain that one copy of each gene was disrupted.
Tetrad analysis of the strain revealed that neither single nor double disruption of the genes affects growth or ER-to-Golgi transport (data not shown).

**Chromosomal disruption of SMY2 exhibits a synthetic lethal interaction with the sec24-20 mutation**

To further examine the genetic interaction between SEC24 and SMY2, we tested whether the chromosomal disruption of SMY2 affects the growth phenotype of the sec24-20 mutant. First, the chromosomal disruption of SMY2 (Δsmy2) was introduced into a yeast strain YKH3, which contained the sec24 null (Δsec24) mutation but was rescued by the plasmid pSEC24 (pAN1; SEC24, CEN, URA3), to generate a new yeast strain YNHY3 (Δsec24Δsmy2). Δsec24 (YKH3) and Δsec24Δsmy2 (YNHY3) strains were then transformed with the plasmid psec24-20 (pAN12; sec24-20, CEN, TRP1), and the resulting transformants were streaked onto selective media (MVD) plates containing 5-fluoro-5-2000; 9: 79–93

Figure 2: Smy2p and Ypl105cp.

A) Schematic representation of Smy2p and its homologue Ypl105cp indicating conserved regions and consensus motifs present at comparable sites. Amino acid sequences around the GYF domain of Smy2p and consensus sequence of the domain are also indicated.

B) Hydropathy profile of Smy2p calculated as described by Kyte and Doolittle (72).

C) sec24-20 (YNHY2) cells containing pSMY1 (SMY2, 2µ, YPL105c, 2µ) or pRS426 (vector) were streaked on MVD plates and incubated at the indicated temperatures for 3 days. The amino acids underlined denote the consensus motif of the GYF domain.

Figure 3: SMY2 disruption exhibits severe growth defect in the sec24-20 background. Δsec24 cells being rescued by pSEC24 (pAN1; SEC24, CEN, URA3) (YKH3) and Δsec24Δsmy2 cells being rescued by psec24-20 (pAN12; sec24-20, CEN, TRP1) or pRS314 (vector). The transformants were streaked onto MVD (control) and MVD containing 5-FOA (5-FOA) plates and incubated at 23°C for 3 days.
the high-copy (2µ) SMY2 plasmid was introduced into various temperature-sensitive mutants defective in vesicular transport between the ER and the Golgi, and the suppression activity was tested (Table 1). The high-copy (2µ) expression of SMY2 suppressed the temperature-sensitive growth defect of the following mutants defective in ER-to-Golgi transport: sec16-2 (COPII vesicle formation), sec22-3 and bet1-1 (ER–Golgi SNAREs), and sec34-1 and sec35-1 (vesicle tethering to the Golgi), but not mutants defective in vesicle fusion or Golgi-to-ER transport. The low-copy (CEN) expression of SMY2 could suppress only the growth defect of sec24-20.

We then examined whether the chromosomal disruption of SMY2 affects the temperature-sensitive growth of mutants defective in ER-to-Golgi transport. Among the strains tested, we found that Δsmy2 exhibited weak synthetic negative interactions with sec13-1 (COPII vesicle formation) and sec22-3 (ER–Golgi SNARE) (data not shown).

Together, our genetic observations suggest that SMY2 is involved in the ER-to-Golgi transport, especially in the COPII vesicle formation.

**Smy2p localization**

To examine the intracellular distribution of Smy2p, three repeats of the influenza virus hemagglutinin (HA) epitope were tagged at its carboxyl terminus. Epitope-tagged SMY2 (SMY2-3HA) was judged to be functional because

### Table 1: Effect of SMY2 overexpression on the growth of temperature-sensitive mutants defective in vesicular transport between the ER and the Golgi

| Function                        | Strain        | Plasmid | Incubation temperature (°C) |
|---------------------------------|---------------|---------|----------------------------|
|                                 |               |         | 26 | 28 | 30 | 32 | 34 | 35 | 37 |
| **COPII vesicle formation**     |               |         |    |    |    |    |    |    |    |
| sec12-4                         | vector        | +       | +  | +  | ±  | –  | –  | –  | –  |
| SMY2(2µ)                        | +             | +       | +  | –  | –  | –  | –  | –  | –  |
| sar1-2                          | vector        | +       | +  | ±  | –  | –  | –  | –  | –  |
| SMY2(2µ)                        | +             | +       | –  | –  | –  | –  | –  | –  | –  |
| sec23-1                         | vector        | +       | +  | ±  | –  | –  | –  | –  | –  |
| SMY2(2µ)                        | +             | +       | –  | –  | –  | –  | –  | –  | –  |
| sec23-2                         | vector        | +       | +  | ±  | –  | –  | –  | –  | –  |
| SMY2(2µ)                        | +             | +       | –  | –  | –  | –  | –  | –  | –  |
| sec13-1                         | vector        | +       | +  | ±  | –  | –  | –  | –  | –  |
| SMY2(2µ)                        | +             | +       | –  | –  | –  | –  | –  | –  | –  |
| sec4-20                         | vector        | +       | +  | ±  | –  | –  | –  | –  | –  |
| SMY2(2µ)                        | +             | +       | –  | –  | –  | –  | –  | –  | –  |
| sec31-1                         | vector        | +       | +  | ±  | –  | –  | –  | –  | –  |
| SMY2(2µ)                        | +             | +       | –  | –  | –  | –  | –  | –  | –  |
| sec16-2                         | vector        | +       | +  | ±  | –  | –  | –  | –  | –  |
| SMY2(2µ)                        | +             | +       | –  | –  | –  | –  | –  | –  | –  |
| **ER–Golgi SNAREs**             |               |         |    |    |    |    |    |    |    |
| sec22-3                         | vector        | +       | +  | –  | –  | –  | –  | –  | –  |
| SMY2(2µ)                        | +             | +       | –  | –  | –  | –  | –  | –  | –  |
| bet1-1                          | vector        | +       | +  | ±  | –  | –  | –  | –  | –  |
| SMY2(2µ)                        | +             | +       | –  | –  | –  | –  | –  | –  | –  |
| sec34-1                         | vector        | +       | +  | ±  | –  | –  | –  | –  | –  |
| SMY2(2µ)                        | +             | +       | –  | –  | –  | –  | –  | –  | –  |
| sec35-1                         | vector        | +       | +  | ±  | –  | –  | –  | –  | –  |
| SMY2(2µ)                        | +             | +       | –  | –  | –  | –  | –  | –  | –  |
| **Vesicle tethering to the Golgi** |               |         |    |    |    |    |    |    |    |
| sec34-1                         | vector        | +       | +  | ±  | –  | –  | –  | –  | –  |
| SMY2(2µ)                        | +             | +       | –  | –  | –  | –  | –  | –  | –  |
| sec35-1                         | vector        | +       | +  | ±  | –  | –  | –  | –  | –  |
| SMY2(2µ)                        | +             | +       | –  | –  | –  | –  | –  | –  | –  |
| **Vesicle fusion**              |               |         |    |    |    |    |    |    |    |
| sec17-1                         | vector        | +       | +  | ±  | –  | –  | –  | –  | –  |
| SMY2(2µ)                        | +             | +       | –  | –  | –  | –  | –  | –  | –  |
| sec18-1                         | vector        | +       | ±  | –  | –  | –  | –  | –  | –  |
| SMY2(2µ)                        | +             | ±       | –  | –  | –  | –  | –  | –  | –  |
| **Golgi-to-ER transport**       |               |         |    |    |    |    |    |    |    |
| sec20-1                         | vector        | +       | ±  | –  | –  | –  | –  | –  | –  |
| SMY2(2µ)                        | +             | ±       | –  | –  | –  | –  | –  | –  | –  |
| sec21-1                         | vector        | +       | ±  | –  | –  | –  | –  | –  | –  |
| SMY2(2µ)                        | +             | ±       | –  | –  | –  | –  | –  | –  | –  |
| sec27-1                         | vector        | +       | ±  | –  | –  | –  | –  | –  | –  |
| SMY2(2µ)                        | +             | ±       | –  | –  | –  | –  | –  | –  | –  |
| ret1-1                          | vector        | +       | ±  | –  | –  | –  | –  | –  | –  |
| SMY2(2µ)                        | +             | ±       | –  | –  | –  | –  | –  | –  | –  |
| ret3-1                          | vector        | +       | ±  | –  | –  | –  | –  | –  | –  |
| SMY2(2µ)                        | +             | ±       | –  | –  | –  | –  | –  | –  | –  |

*aMutants containing pSMY1 (SMY2, 2µ) or pRS426 (vector) were incubated on MVD plate for 3–4 days at the indicated temperatures, respectively.*

Traffic 2008; 9: 79–93
it suppressed the sec24-20 phenotypes to the same extent as untagged SMY2 (data not shown). SMY2-3HA was introduced into Δsmy2 (YNH4) strain by either a low-copy (CEN) or a high-copy (2μ) vector, and whole cell lysates prepared from the transformants were analyzed by immunoblotting with the anti-HA antibody (Figure 4A). Smy2-3HAp was detected as a protein with apparent molecular mass of 100 kDa that is higher than the predicted molecular mass of 87 kDa, probably because of its high isoelectric point of 8.97 as predicted by its amino acid composition. While the suppression activity for the sec24-20 mutation was comparable (Figure 1A), the low-copy (CEN) SMY2-3HA plasmid gave much lower expression of Smy2-3HAp than the high-copy (2μ) plasmid.

Smy2p is predicted to be a hydrophilic protein containing neither signal sequence nor transmembrane domain (Figure 2B). To examine possible membrane association of Smy2p, the whole cell lysate from Δsmy2 (YNH4) cells containing the low-copy (CEN) SMY2-3HA plasmid was subjected to 100 000 × g centrifugation, and the resulting supernatant (S₁) and pellet (P₁) fractions were analyzed by immunoblotting (Figure 4B). Unexpectedly, whereas the peripheral membrane protein Sec24p was detected in both S₁ and P₁ fractions, Smy2-3HAp was detected only in the P₁ fraction like the integral membrane protein Dpm1p (51,52). To further examine the nature of membrane association of Smy2p, the P₁ fraction was treated with buffer containing 0.5 M NaCl (NaCl), 2.5 M urea (Urea), 0.1 M Na₂CO₃ (pH 11) or 1% Triton-X-100, centrifuged at 100 000 × g, and the resulting supernatant (S₂) and pellet (P₂) fractions were analyzed by immunoblotting. As shown in Figure 4C, the integral membrane protein Dpm1p was solubilized only by 1% Triton-X-100, but Smy2-3HAp was efficiently solubilized by 2.5 M urea or 0.1 M Na₂CO₃ as the peripheral membrane protein Sec24p. These results strongly suggest that Smy2p is a peripheral membrane protein with no soluble pool, but not an integral membrane protein.

As our genetic observation suggests the involvement of Smy2p in COPII vesicle formation, the most plausible intracellular localization of Smy2p may be the ER membrane. To address this, the 100 000 × g pellet fraction of the lysate was subjected to a subcellular fractionation analysis by velocity sedimentation on a sucrose density gradient, and the distribution of Smy2-3HAp was compared with that of marker proteins of the ER and the Golgi by immunoblotting (Figure 5A). Notably, Smy2-3HAp was co-sedimented with COPII components Sec24p and Sec31p in the fractions 8–10 in which the ER marker Sec61p was more abundant than the Golgi marker Kex2p. This result suggests that Smy2p is localized on the surface of the ER together with COPII components. Similar results were obtained from the subcellular fractionation analysis by flotation equilibrium in a sucrose density gradient, confirming that Smy2p associates with membranes but not with cytoskeletons (data not shown).

Finally, we examined the intracellular localization of Smy2p by microscopic analysis. Δsmy2 (YNH4) cells containing the low-copy (CEN) SMY2-3HA plasmid were subjected to indirect immunofluorescence analysis with the anti-HA antibody. As shown in Figure 5B, many, if not all, cells exhibited concentrated staining around the DAPI-stained nucleus, reminiscent of the perinuclear localization of Smy2p.
localization of ER-resident proteins (53,54). In addition, cells often exhibited weak punctate staining dispersed in the cell body. This staining pattern of Smy2-3HAp was similar to that of Sec16p, a peripheral membrane protein localized on the ER (26).

Together, these biochemical and morphological observations suggest that Smy2p is a peripheral membrane protein associated with the COPII-enriched ER membrane.

*Smy2p is not present on COPII vesicles formed in vitro*

Is Smy2p incorporated into COPII vesicles or statically localized on the ER? To address this, we performed an in vitro vesicle budding assay with purified COPII components and salt-washed microsomes, which were prepared from Δsmy2 (YNH4) cells containing the low-copy (CEN) SMY2-3HA plasmid. The salt wash allowed Smy2-3HAp to remain associated with microsomes. As shown in Figure 6, the ER–Golgi SNARE Sec22p was efficiently incorporated into vesicle fraction, but Smy2-3HAp and the negative control Sec61p were not. Thus, Smy2p is likely to localize statically on the ER membrane.

We tried to compare the efficiency of vesicle formation among the salt-washed microsomes, which were prepared from YNH4 Δsmy2 cells containing the low-copy (CEN) or the high-copy (2μ) SMY2-3HA plasmid or an empty vector. As far as we examined, however, no difference was observed under our experimental conditions.

*Figure 5: Smy2p is localized on ER membrane.* A) A whole cell lysate from Δsmy2 (YNH4) cells containing pSMY4 (SMY2-3HA, CEN) was centrifuged at 100 000 × g. The resulting pellet fraction (mem) was resuspended in sucrose solution and separated on a 20–60% sucrose density gradient. Twelve fractions were collected from the top, resolved by SDS–PAGE and immunoblotted with the anti-HA, anti-Sec24p, anti-Sec31p, anti-Sec61p or anti-Kex2p antibody. Relative amounts of these proteins in each fraction were quantified by densitometry of immunoblots. B) Yeast cells used in A were examined by indirect immunofluorescence with the anti-HA antibody (left panels in the pair). DAPI staining was used to visualize the nuclei (right panels in the pair).

*Figure 6: Smy2p is not incorporated into COPII vesicles.* Salt-washed microsomes prepared from Δsmy2 (YNH4) cells containing pSMY4 (SMY2-3HA, CEN) were incubated with (+) or without (−) purified COPII proteins in the presence of guanyl-5′-yl imidodiphosphate. One tenth of the total reaction (T) and the budded COPII vesicles separated from donor membranes by centrifugation were resolved by SDS–PAGE and immunoblotted with anti-HA, anti-Sec22p or anti-Sec61p antibody. Relative amounts of these proteins incorporated into COPII vesicles were quantified by densitometry of immunoblots.
that utilize the wild-type COPII components for vesicle formation (data not shown).

Smy2p and a COPII subcomplex, Sec23p/Sec24p, are coimmunoprecipitated in specific COPII mutants
The results obtained so far support the idea that Smy2p might be functioning during COPII vesicle formation together with COPII components, especially with Sec24p. We therefore decided to examine whether Smy2p physically interacts with COPII components. In order to investigate their biochemical interaction in various mutant backgrounds, we performed coimmunoprecipitation experiments using Triton-soluble fractions of whole cell lysates, even though they contained small amounts of soluble Smy2-3HAp and COPII components (Figure 4). First, whole cell lysates from wild-type (YNH1) and sec24-20 (YNH2) cells containing the low-copy (CEN) SMY2-3HA plasmid (cultured at 23°C) were solubilized by 1% Triton-X-100, centrifuged at 17,400 × g for 30 min at 4°C and the resulting supernatants were subjected to immunoprecipitation with the anti-HA antibody. Immunoprecipitates were then analyzed by immunoblotting with antibodies against COPII components. As shown in Figure 7A, we were able to pull down Smy2-3HAp with the anti-HA antibody from the Triton-soluble fractions of both strains and found that Sec24p and Sec23p, but not Sec31p, were coimmunoprecipitated with Smy2-3HAp in the sec24-20 mutant background. In contrast, no coimmunoprecipitation was observed in the wild-type background.

Next, to examine whether this protein–protein interaction is specific for the sec24-20 background or is a general consequence of the reduced ER-to-Golgi transport, we performed the coimmunoprecipitation experiments using the Triton-soluble fractions of whole cell lysates prepared from the following temperature-sensitive mutants defective in ER-to-Golgi transport (cultured at 23°C): sec12-4, sec13-1, sec16-2, sec23-1, sec24-20 (COPII vesicle formation), sec34-1, sec35-1 (vesicle tethering to the Golgi) and sec22-3 (ER–Golgi SNARE), which contain the low-copy (CEN) SMY2-3HA plasmid. Again, Smy2-3HAp was successfully recovered from the Triton-soluble fractions from all strains tested (Figure 7B). Surprisingly, the coimmunoprecipitation was observed in sec23-1 and sec24-20, but not in other mutant backgrounds. Similar results were obtained from whole cell lysates from the mutants incubated at the restrictive temperature of 33°C at which the ER-to-Golgi transport is severely inhibited (data not shown). These results strongly suggest that the fraction of Smy2-3HAp

Figure 7: COPII subcomplex Sec23p/Sec24p is coprecipitated with Smy2p in sec23 and sec24 backgrounds.
A) Whole cell lysates from wild-type (WT; YNH1) and sec24-20 (YNH2) cells containing pSMY4 (SMY2-3HA, CEN) or pRS316 (Vector) (cultured at 23°C) were solubilized with 1% Triton-X-100. After centrifugation at 17,400 × g for 30 min at 4°C, supernatants were subjected to immunoprecipitation with (+) or without (−) the anti-HA antibody. The lysates (Lysate) and immunoprecipitates (IP) were resolved by SDS-PAGE and immunoblotted (IB) with the anti-HA, anti-Sec24p, anti-Sec23p or anti-Sec31p antibody. B) Whole cell lysates from sec12-4 (MBY10-7A), sec23-1 (RSY282), sec24-20 (YNH2), sec13-1 (RSY268), sec16-2 (RSY268), sec34-1 (YNH5), sec35-1 (YNH6) and sec22-3 (RSY942) cells containing pSMY4 (cultured at 23°C) were analyzed by immunoprecipitation as in A.
solubilized by Triton-X-100 treatment was indeed interacting with the Sec23p/Sec24p subcomplex only in the sec24-20 or sec23-1 background, which seems to be a specific consequence of the dysfunction of Sec23p or Sec24p, rather than the general consequence of reduced ER-to-Golgi transport.

**Two-hybrid interaction between Smy2p and Sec23p**

The interaction between Smy2p and the Sec23p/Sec24p subcomplex was also examined by the yeast two-hybrid system. Smy2p was fused to the LexA-DNA binding domain and tested for interaction with Sec23p and Sec24p, which were connected to the B42 acidic activation domain. Interaction was detected by the level of β-galactosidase expression in yeast from a LacZ reporter gene carrying LexA operator sites in the promoter. Unexpectedly, interaction was detected between Smy2p and Sec23p, but not between Smy2p and Sec24p (Table 2). The β-galactosidase activity for this interaction was much lower than that for the highly stable interaction between Sec23p and Sec24p (as a positive control), suggesting that Smy2p weakly or transiently associates with Sec23p. Nevertheless, this two-hybrid interaction seems to represent, at least, a part of the nature of coimmunoprecipitation between Smy2p and the Sec23p/Sec24p subcomplex.

**Overexpression of Smy2p suppresses the sec24-20 phenotypes through the interaction with Sec23p/Sec24p subcomplex**

We performed a mutational analysis of Smy2p to identify the regions required for the suppression of sec24-20 phenotypes and for the interaction with Sec23p/Sec24p subcomplex. First, a series of mutant smy2 genes with 3HA epitope at their carboxyl termini were constructed and introduced on the low-copy (CEN) vector into sec24-20 (YNH2) cells to examine their suppression activity (Figure 8A). The suppression activity was severely reduced when the consensus sequence of the GYF domain (GPF-X7-W-X3-GYF) was disrupted by amino acid substitutions (mutant A) or deletion (mutant B). The deletion of the coiled-coil domain did not affect the suppression activity (mutant C). We also found that the amino-terminal region alone, which contained the GYF domain (amino acid residues 1–336), exhibited a low level of suppression activity (mutant D), and this was restored to the wild-type level by fusion with the carboxyl-terminal portion containing amino acid residues 501–676 (mutant F) but not with residues 677–790 (mutant E). Another amino- and carboxy-terminal fusion containing amino acid residues 1–500 and 677–790 also showed a high suppression activity (mutant G). However, the carboxyl-terminal portion alone was insufficient for the suppression (mutants H and I). These results suggest that the combination of the intact GYF domain and a certain length of the carboxyl-terminal domain is required for the suppression.

We then examined whether these mutant Smy2p interact with Sec23p/Sec24p subcomplex by coimmunoprecipitation analysis in the sec24-20 background as described above. As shown in Figure 8B, the Sec23p/Sec24p subcomplex was coimmunoprecipitated with the GYF mutants (mutants A and B) or the coiled-coil mutant (mutant C), suggesting that these domains are not involved in the interaction. Notably, the amino-terminal portion alone (amino acid residues 1–336) failed to coimmunoprecipitate Sec23p/Sec24p (mutant D), and the fusion with a certain length of the carboxyl-terminal portion restored the coimmunoprecipitation (mutants F and G). Again, the carboxyl-terminal portion alone exhibited no coimmunoprecipitation (mutants H and I). These results suggest that neither the GYF nor the coiled-coil domain alone, but a larger part of Smy2p, is required for the interaction with Sec23p/Sec24p subcomplex.

Taken together, these genetic and biochemical analyses indicate that all mutant Smy2p with the suppression activity could coimmunoprecipitate Sec23p/Sec24p and that the strength of the suppression well correlated with the amount of the Sec23p/Sec24p subcomplex coimmunoprecipitated. Thus, the interaction between Smy2p and the Sec23p/Sec24p subcomplex is probably a prerequisite for the suppression of the sec24-20 phenotypes by overexpression of SMY2.

**Discussion**

In this study, we isolated SMY2 as a suppressor of the temperature-sensitive sec24-20 mutant. We first excluded the possibility that endogenous Sfb2p (Iss1p), a functionally redundant SEC24 homologue, is involved in the suppression

| B42 acidic activation domain fused to | no fusion | SEC23 | SEC24 |
|------------------------------------|-----------|-------|-------|
| **LexA-DNA binding domain fused to** | no fusion | 4.58 ± 0.54 | 1.09 ± 0.45 | 2.11 ± 1.32 |
| MY2 | 3.57 ± 1.21 | 26.03 ± 11.15 | 1.62 ± 0.53 |
| SEC24 | 7.53 ± 1.77 | 401.40 ± 41.23 | Not determined |

*β*-Galactosidase activity (units). EGY48 cells containing plasmids encoding a LexA fusion protein (pEG202, pEG-SMY2 or pEG-SEC24), a B42 fusion protein (pJG4-5, pJG-SEC23 or pJG-SEC24) and a reporter plasmid (pSH18-34) were grown in raffinose/galactose medium for 10 h before the assay to induce expression of B42 fusion proteins.

**Table 2**: Two-hybrid interaction between Smy2p and Sec23p

Traffic 2008; 9: 79–93
by overexpression of SMY2 (Figure 1C). It is more unlikely that the suppression involves endogenous Sfb3p (Lst1p) as its overexpression cannot suppress the temperature-sensitive growth defect of the sec24 mutants (17,18). Thus, we concluded that SMY2 is a novel suppressor of the sec24-20 mutant and further characterized its properties.

The Saccharomyces genome contains the SMY2 homologue YPL105c (48–50), but its overexpression failed to suppress any mutants defective in vesicular transport between the ER and the Golgi (Figure 2C and our unpublished observation). In addition, immunofluorescence staining of Ypl105c-3HAp did not show the perinuclear ER-like pattern, as was the case with Smy2-3HAp (our unpublished observation). Thus, we consider that despite the sequence similarity, Ypl105cp is not the functional Smy2p homologue.

Genetic analysis revealed that all mutations suppressed by the high-copy (2μ) expression of SMY2 are linked to the ER-to-Golgi transport (Table 1). SMY2 exhibited particularly strong genetic interaction with SEC24 (Figures 1 and 3). This may suggest that Smy2p functions cooperatively with Sec24p in COPII vesicle formation. However, considering other mutations suppressed by the high-copy (2μ) expression of SMY2, other possibilities cannot be ruled out. For example, Smy2p might function in tethering (sec34-1 and sec35-1) and/or fusion (sec22-3 and bet1-1) of ER-derived vesicle to the Golgi membrane. The intimate relationship between COPII vesicle formation and vesicle tethering/fusion to the Golgi membrane in mammalian cells (55) also leaves a possibility that Smy2p might affect indirectly on these aspects of ER-to-Golgi transport from the stage of COPII vesicle formation in yeast.
Biochemical and morphological analyses suggested that Smy2p is a peripheral ER membrane protein co-fractionated with COPII components (Figures 4 and 5). However, in vitro vesicle budding assay revealed that Smy2p is not incorporated into COPII vesicles (Figure 6), suggesting that Smy2p acts as neither coat nor cargo protein, but is stably localized on the ER and facilitates COPII vesicle formation.

Coimmunoprecipitation analysis revealed that Smy2p specifically interacts with the Sec23p/Sec24p subcomplex in sec24-20 and sec23-1 mutants (Figure 7). This observation may represent prolonged interaction of the proteins in these mutant backgrounds and implies that Smy2p assists some Sec23p/Sec24p-deficient process during COPII vesicle formation, while the interaction may be too transient to be detected by coimmunoprecipitation in wild-type cells. We further found that the interaction between Smy2p and the Sec23p/Sec24p subcomplex appears to be a prerequisite for the suppression of the sec24-20 phenotypes by overexpression of SMY2 (Figure 8). What is then the mechanism of the suppression? The sec24-20 gene has a mutation by which the 897th codon (TGG) encoding tryptophan (W897) is changed to a termination codon (TGA) (our unpublished observation), resulting in producing Sec24-20p, a truncated Sec24p lacking the carboxyl-terminal 30 amino acids. This short carboxyl-terminal region is shown to locate on the membrane-proximal surface (56). Moreover, W897 is located in the cargo recognition ‘A-site’ and is shown to be important for Sed5p binding (13,14,57). As the sec24-20 mutant exhibits growth arrest and the blockage of ER-to-Golgi transport at the restrictive temperature, without obvious accumulation of vesicles (17), we consider that the Sec23p/Sec24p-20p subcomplex probably becomes defective in COPII vesicle formation at high temperatures because of the weakened interaction with membranes and/or membrane proteins such as Sed5p. If this is the case, the suppression by excess Smy2p could be accounted for by the possibility that Smy2p acts as a scaffold or a platform for the assembly of COPII coat, which directly binds Sec23p/Sec24p, like the essential scaffold protein Sec16p (26–29). An increased amount of Smy2p may provide the additional scaffold or platform, leading to the compensation for the impaired function of Sec23p/Sec24-20p. This idea is supported by the suppression of the sec16-2 mutation by the high-copy (2µ) expression of SMY2 (Table 1) and the two-hybrid interaction between Smy2p and Sec23p (Table 2). Synthetic lethal interaction between sec24-20 and chromosomal deletion of SMY2 (Figure 3) is also consistent with this idea. Finally, it is unlikely that Smy2p modulates the GTPase cycle of Sar1p because the overexpression of SMY2 did not suppress or exacerbate the temperature-sensitive growth defect of the mutants, sec23-1, sec23-2 (encoding a GAP for Sar1p), sec12-4 (encoding a GEF for Sar1p) and sar1-2 (Table 1). Further extensive biochemical studies will be necessary for understanding the nature of defect in the sec24-20 mutant and the mode of its suppression by Smy2p.

Mutational analysis of Smy2p revealed that its GYF domain, a proline-rich sequence binding module, is required for the suppression of the sec24-20 phenotypes but not responsible for the interaction with Sec23p/Sec24p subcomplex (Figure 8). This suggests that the GYF domain mediates the interaction between Smy2p and another protein that is also required for the suppression of the sec24-20 phenotypes. Genome-wide two-hybrid analysis has shown that Smy2p interacts with Msil5p and Mud2p, nuclear proteins involved in messenger RNA splicing (58). However, it is unlikely that these nuclear proteins facilitate the COPII vesicle formation co-operatively with Smy2p on the ER membrane. Identification of additional Smy2p-interacting protein will be helpful to understand the molecular mechanism by which Smy2p facilitates COPII vesicle formation.

Finally, our work strongly suggests that Smy2p is an accessory protein that facilitates COPII vesicle formation. Recently, such putative accessory proteins have also been identified on ER exit sites of mammalian cells. The nucleoside diphosphate kinase Nm23H2 facilitates COPII vesicle formation independent of its kinase activity (59). The protein kinase PCTAIRE, which has been identified as a Sec23p-interacting protein, requires its kinase activity for ER exit of secretory cargo but not for the interaction with Sec23p (60). In addition, the Ca2+/-binding protein ALG-2 (apoptosis-linked gene 2) interacts with Sec31p in a Ca2+-dependent manner (61), and the phospholipase A1-related protein p125 interacts with Sec23p (62). These proteins are possibly required for modulating COPII vesicle formation and/or organizing ER exit sites. Besides Sec16p, Sed4p and the Yip1p–Yif1p–Yos1p complex (see Introduction), these findings together with our findings further support the view that, in living cells, COPII vesicle formation is a more complicated process than that reconstituted in vitro with minimal components. Identification and detailed characterization of accessory proteins may provide novel insights into the regulation of COPII vesicle formation under physiological conditions.

Materials and Methods

Yeast strains and media
Saccharomyces cerevisiae strains used in this study are listed in Table 3. Cells were grown in MVD medium (0.67% yeast nitrogen base without amino acids (Difco Laboratories Inc.) and 2% glucose), MCD medium (MVD containing 0.5% casamino acids (Difco Laboratories Inc.) or SC-raffinose (0.67% yeast nitrogen base without amino acids, 0.06% dropout mix (63) and 2% raffinose) with appropriate supplements.

Plasmid construction
Construction of SEC24 plasmids, pAN1, pAN11 and pAN12, was described previously (17). The DNA fragment containing SMY2 was obtained from genomic DNA by polymerase chain reaction (PCR) with the primers 5’-AGAGAGGGCCGGCGATACATCGTCGAAAGCCATGTCCAGGTTTGTGAGTATG-3’ and 5’-AGAGAGGGAGAGCTCGTGCCTACTGTGTGCAAAGATATG-3’, digested by SnaI and NotI and subcloned into the SacI–NotI sites of pRS426 (64) and
**Table 3**: Yeast strains used in this study

| Strain   | Genotype                        | Reference/Source |
|----------|---------------------------------|------------------|
| YPH500   | MATa ura3 trp1 his3 leu2 lys2 ade2 | (65)             |
| YPH501   | MATa/MATa ura3/trp1/his3/trp1/lys2/leu2/lys2/ade2/ade2 | (65)             |
| YKH3     | MATa ura3 trp1 his3 leu2 2sec24::LEU2 containing pAN1 (SEC24, URA3, CEN) | (17)             |
| YNH1     | MATa ura3 trp1 his3 leu2 lys2 ade2 2sec24::HIS3 containing pAN11 (SEC24, TRP1, CEN) | This study       |
| YNH2     | MATa ura3 trp1 his3 leu2 lys2 ade2 2sec24::HIS3 containing pAN12 (sec24-20, TRP1, CEN) | This study       |
| YNH3     | MATa ura3 trp1 his3 leu2 lys2 ade2 2sec24::HIS3 containing pAN1 | This study       |
| YNH4     | MATa ura3 trp1 his3 leu2 lys2 ade2 2smy2::HIS3 | This study       |
| YNH5     | MATa ura3 his3 lys2 sec34-1 | This study       |
| YNH6     | MATa ura3 trp1 leu2 lys2 sec35-1 | This study       |
| YNH7     | MATa ura3 trp1 his3 leu2 2sec24::LEU2 containing pAN12 (sec24-20, TRP1, CEN) | This study       |
| YNH8     | MATa ura3 trp1 his3 leu2 2sec24::LEU2 2sfb2::HIS3 containing pAN12 (sec24-20, TRP1, CEN) | This study       |
| MBY10-7A | MATa ura3 trp1 his3 his4 leu2 sec2 gal2 sec12-4 | (4)              |
| TOY224   | MATa ura3 trp1 his3 leu2 lys2 ade2 2sar1::HIS3 2pep4::ADE2 containing pMYY3-9 (sar1E112K (sar1-2), TRP1, CEN) | (73)             |
| RSY266   | MATa ura3 his4 sec13-1 | R. Schekman*     |
| RSY268   | MATa ura3 sec16-2 | R. Schekman       |
| RSY270   | MATa ura3 his4 sec17-1 | R. Schekman       |
| RSY11    | MATa ura3 leu2 sec2 sec18-1 | R. Schekman       |
| RSY276   | MATa ura3 his4 sec20-1 | R. Schekman       |
| RSY278   | MATa ura3 his4 sec21-1 | R. Schekman       |
| RSY942   | MATa ura3 leu2 sec22-3 | R. Schekman       |
| RSY82    | MATa ura3 leu2 sec23-1 | R. Schekman       |
| RSY639   | MATa ura3 leu2 sec23-2 | R. Schekman       |
| RSY1312  | MATa ura3 trp1 leu2 sec27-1 | R. Schekman       |
| RSY1004  | MATa ura3 leu2 sec31-1 | R. Schekman       |
| RSY958   | MATa lys2 sec34-1 | R. Schekman       |
| RSY962   | MATa lys2 sec35-1 | R. Schekman       |
| RSY944   | MATa ura3 lys2 bet1-1 | R. Schekman       |
| EGY101   | MATa ura3 trp1 his3 leu2 suc2 ret1-1 | F. Letourneur*   |
| FLY89    | MATa ura3 trp1 his3 leu2 suc2 ret3-1 | F. Letourneur     |
| EGY48    | MATa ura3 trp1 his3 leu2:LexAop-LEU2 | OriGene Technologies Inc.* |

*University of California, Berkeley, Berkeley, CA, USA.

*UMR5086 CNRS/Université Lyon I, Lyon, France.

pRS316 (65) to produce pSMY1 and pSMY3, respectively. Similarly, the DNA fragment containing YPL105c was obtained by PCR with the primers containing a BamHI or EcoRI site at their 5’ termini (5’-AGAGAGAGGATCCGTTAGTGCTAGGTTCCCTCCG-3’ and 5’-AGAGAGAGAATTCACCTTCTCATCCTTTGACAG-3’). The primers containing Sec23p and Sec24p, respectively. Similarly, pEG-SEC24 was constructed with pEG202 and the ORF of SEC23 encoding the Sec23p was fused in frame with the B42 acidic activation domain at the N-terminus of the LexAop/pEG202 protein.

| Antibodies |
|------------|
| The anti-Sec22p, anti-Sec23p, anti-Sec24p, anti-Sec31p and anti-Sec61p antibodies were gifts from R. Schekman (University of California, Berkeley, CA, USA). |

Sec22p, Sec23p, Sec24p, Sec31p and Sec61p are components of the secretory pathway in yeast. Sec22p is a member of the Sec61p family of translocon components, Sec23p is a member of the Sec12p family of translocon components, and Sec24p is a member of the Sec24p family of translocon components. Sec31p is a member of the Sec31p family of translocon components, and Sec61p is a member of the Sec61p family of translocon components. The anti-Sec22p, anti-Sec23p, anti-Sec24p, anti-Sec31p and anti-Sec61p antibodies were gifts from R. Schekman (University of California, Berkeley, CA, USA).
Metabolic labeling and immunoprecipitation of CPY and Gas1p

Pulse–chase experiments were performed as described previously (68,69). Yeast cells grown exponentially in MCD medium were labeled with 25 Ci of [35S]Met. After 1 h of labeling, the cells were washed free of extracellular radioactive material and chased for appropriate times. Markers proteins, CPY and Gas1p, were recovered from the same cell lysates by immunoprecipitation with anti-CPY and anti-Gas1p at 1:5000 dilution, resolved by SDS–PAGE and visualized with a BAS2500 image analyzer (Fuji Photo Film). Amounts of mature forms of CPY and Gas1p were quantitated with Image Gauge version 3.4B software (Fuji Photo Film) and expressed as %maturation.

Subcellular fractionation

Subcellular fractionation was performed as described previously (70) with the following modifications. A whole cell lysate prepared from log-phase yeast cells was centrifuged at 100,000 g for 30 min at 4 °C. The resulting supernatant was rotated overnight with protein G-immobilized anti-HA (12CA5) antibody at 4 °C. The beads were washed four times with wash buffer (IP buffer without skim milk) and boiled in the SDS–PAGE sample buffer (50 mM Tris–HCl, pH 6.8, 1% sodium dodecyl sulfate, 10% glycerol and 0.01% bromophenol blue) containing 0.1% dithiothreitol. The eluates were analyzed by SDS–PAGE and immunoblotting.

Yeast two-hybrid assay

Sec23p and Sec24p were tested for binding to Smy2p with a DupLEX-A yeast two-hybrid system (OriGene Technologies Inc.). EGY48 strains were transformed with combinations of control or fusion protein plasmids described under Plasmid construction together with a LacZ reporter plasmid pSH18-34. The resulting transformants were grown to a log phase in SC-raffinose medium, then galactose was added to a final concentration of 2% and growth continued for 10 h. β-Galactosidase assay with permeabilized cells was performed as described previously (63).

Acknowledgments

We are grateful to R. Schekman (University of California, Berkeley) for yeast strains and antibodies, F. Letourneau (IIBP/UMR5086 CNRS) for yeast strains, H. Riezman (University of Basel) for the anti-Gas1p antibody, K. Kohno (Nara Institute of Science and Technology) for plasmids and members of the Nakano laboratory for valuable discussions. H. H. was a special postdoctoral researcher of RIKEN Discovery Research Institute. This work was supported by grants-in-aid from the Ministry of Education, Culture, Sports, Science and Technology of Japan and by the fund from the Bioarchitect Project of RIKEN.

References

1. Schekman R, Orci L. Coat proteins and vesicle budding. Science 1996;271:1526–1533.

2. Nakano A, Muramatsu M. A novel GTP-binding protein, Sar1p, is involved in transport from the endoplasmic reticulum to the Golgi apparatus. J Cell Biol 1989;109:2677–2691.

3. Barlowe C, Orci L, Yeung T, Hosobuchi M, Hamasoto S, Salama N, Rexach MF, Ravazzola M, Amherdt M, Schekman R. COPI: a membrane coat formed by Sec proteins that drive vesicle budding from the endoplasmic reticulum. Cell 1994;77:895–907.

4. Nakano A, Brada D, Schekman R. A membrane glycoprotein, Sec12p, required for protein transport from the endoplasmic reticulum to the Golgi apparatus in yeast. J Cell Biol 1988;107:851–863.

5. Barlowe C, Schekman R. SEC12 encodes a guanine-nucleotide-exchange factor essential for transport vesicle budding from the ER. Nature 1993;365:347–349.

6. Bonifacino JS, Glick BS. The mechanisms of vesicle budding and fusion. Cell 2004;115:153–166.

7. Yoshishita T, Barlowe C, Schekman R. Requirement for a GTPase-activating protein in vesicle budding from the endoplasmic reticulum. Science 1993;259:1466–1468.

8. Sato K, Nakano A. Reconstitution of coat protein complex II (COPIII) vesicle formation from cargo-reconstituted proteoliposomes reveals the potential role of GTP hydrolysis by Sar1p in protein sorting. J Biol Chem 2004;279:1330–1335.

9. Aridor M, Weissman J, Bannykh S, Nuoffer C, Balch WE. Cargo selection by the COPII budding machinery during export from the ER. J Cell Biol 1998;141:61–70.

10. Kuehn MJ, Herrmann JM, Schekman R. COPII cargo interactions direct protein sorting into ER-derived transport vesicles. Nature 1998;391:187–190.
Higashio et al.

11. Springer S, Schekman R. Nucleation of COPII vesicular coat complex by endoplasmic reticulum to Golgi vesicle SNAREs. Science 1998;281:698–700.

12. Miller E, Antony B, Hamamoto S, Schekman R. Cargo selection into COPII vesicles is driven by the Sec24p subunit. EMBO J 2002;21:6105–6113.

13. Miller EA, Beilharz TH, Malkus PN, Lee MC, Hamamoto S, Orci L, Schekman R. Multiple cargo binding sites on the COPII subunit Sec24p ensure capture of diverse membrane proteins into transport vesicles. Cell 2003;114:497–509.

14. Mossessova E, Bickford LC, Goldberg J. SNARE selectivity of the COPII coat. Cell 2003;114:483–495.

15. Mancias JD, Goldberg J. The transport signal on Sec22 for packaging into COPII-coated vesicles is a conformational epitope. Mol Cell 2007;26:403–414.

16. Kunihara T, Hamamoto S, Gimeno RE, Kaiser CA, Schekman R, Yoshishita T. Sec24p and Iss1p function interchangeably in transport vesicle formation from the endoplasmic reticulum in Saccharomyces cerevisiae. Mol Biol Cell 2000;11:983–998.

17. Higashio H, Kimata Y, Kiriyama T, Aihara K, Kohno K, SfB2p, a yeast protein related to Sec24p, can function as a constituent of COPII coats required for vesicle budding from the endoplasmic reticulum. J Biol Chem 2000;275:17900–17908.

18. Peng R, Antoni AD, Gallwitz D. Evidence for overlapping and distinct functions in protein transport of coat protein Sec24p family members. J Biol Chem 2000;275:11521–11528.

19. Roberg KJ, Crotwell M, Espenshade P, Gimeno R, Kaiser CA. LST1 is a SEC24 homologue used for selective export of the plasma membrane ATPase from the endoplasmic reticulum. J Cell Biol 1999;145:659–672.

20. Pagano A, Letourneur F, Garcia-Estefania D, Carpentier JL, Orci L, Paccaud JP. Sec24p and Sec23p interacting at the endoplasmic reticulum. J Biol Chem 1999;274:7832–7840.

21. Wendeler MW, Paccaud JP, Hauri HP. Role of Sec24 isoforms in disassembly kinetics during Sar1p-GTP hydrolysis. Nat Struct Mol Biol 1998;5:703–708.

22. Shimoni Y, Kunihara T, Ravazzola M, Amherdt M, Orci L, Schekman R. Lst1p and Sec24p cooperate in sorting of the plasma membrane ATPase into COPII vesicles in Saccharomyces cerevisiae. J Cell Biol 2000;151:973–984.

23. Matsuoka K, Orci L, Amherdt M, Bednarek SY, Hamamoto S, Schekman R, Yeung T. COPII-coated vesicle formation reconstituted with purified coat proteins and chemically defined liposomes. Cell 1998;93:263–275.

24. Matsuoka K, Morimitsu Y, Uchida K, Schekman R. Coat assembly directs v-SNARE concentration into synthetic COPII vesicles. Mol Cell 1998;2:703–708.

25. Sato K, Nakano A. Dissection of COPII subunit-cargo assembly and disassembly kinetics during Sar1p-GTP hydrolysis. Nat Struct Mol Biol 2005;12:167–174.

26. Espenshade P, Gimeno RE, Holzmacher E, Teung P, Kaiser CA. Yeast SEC16 gene encodes a multidomain vesicle coat protein that interacts with Sec23p. J Cell Biol 1995;131:311–324.

27. Gimeno RE, Espenshade P, Kaiser CA. COPII coat subunit interactions: Sec24p and Sec23p bind to adjacent regions of Sec16p. Mol Biol Cell 1996;7:1815–1823.

28. Shaywitz DA, Espenshade P, Gimeno RE, Kaiser CA. COPII subunit interactions in the assembly of the vesicle coat. J Biol Chem 1997;272:25413–25416.

29. Supek F, Madden DT, Hamamoto S, Orci L, Schekman R. Sec16p potentiates the action of COPII proteins to bud transport vesicles. J Cell Biol 2002;158:1029–1038.

30. Conner PL, Eski M, Montega EA, Strongin DE, Levi S, Soderholm J, Glick BS. Sec16 is a determinant of transitional ER organization. Curr Biol 2005;15:1439–1447.

31. Watson P, Townley AK, Koka P, Palmer KJ, Stephens DJ. Sec16 defines endoplasmic reticulum exit sites and is required for secretory cargo export in mammalian cells. Traffic 2006;7:1678–1687.

32. Hardwick KG, Boothroyd JC, Rudner AD, Pelham HR. Genes that allow yeast cells to grow in the absence of the HDEL receptor. EMBO J 1992;11:4187–4198.

33. Gimeno RE, Espenshade P, Kaiser CA. SED4 encodes a yeast endoplasmic reticulum protein that binds Sec16p and participates in vesicle formation. J Cell Biol 1995;131:325–338.

34. Saito Y, Yamashita T, Oka T, Nakano A. Identification of SEC12, SEC4, truncated SEC16, and EK51/HAR3 as multiplicity suppressors of ts mutants of Sar11 GTPase. J Biochem (Tokyo) 1999;125:130–137.

35. Xiong Y, Matern HT, Gallwitz D. Specific binding to a novel and essential Golgi membrane protein (Yip1p) functionally links the transport GTPases Ypt1p and Ypt31p. EMBO J 1998;17:4954–4963.

36. Calero M, Collins RN. Saccharomyces cerevisiae PrA1p/Yip3p interacts with Yip1p and Rab proteins. Biochem Biophys Res Commun 2002;290:678–681.

37. Matern H, Yang X, Andrulis E, Sterngland R, Trepte HH, Gallwitz D. A novel Golgi membrane protein is part of a GTPase-binding protein complex involved in vesicle targeting. EMBO J 2000;19:4485–4492.

38. Heidtman M, Chen CZ, Collins RN, Barlowe C. A role for Yip1p in COPII vesi biogenesis. J Cell Biol 2003;163:57–69.

39. Heidtman M, Chen CZ, Collins RN, Barlowe C. Yos1p is a novel subunit of the Sec16p-Yip1p complex and is required for transport between the endoplasmic reticulum and the Golgi complex. Mol Cell Biol 2005;16:1673–1683.

40. Tang BL, Ong YS, Huang B, Wei S, Wong ET, Qi R, Horstmann H, Hong W. A membrane protein enriched in endoplasmic reticulum exit sites interacts with COPII. J Biol Chem 2001;276:40008–40017.

41. Yoshitisa T, Anarku Y. Nucleotide sequence of AMS1, the structure gene of vacular alpha-mannosidase of Saccharomyces cerevisiae. Biochem Biophys Res Commun 1989;163:908–915.

42. Lillie SH, Brown SS. Immunofluorescence localization of the unconventional myosin, Myo2p, and the putative kinesin-related protein, Smy1p, to the same regions of polarized growth in Saccharomyces cerevisiae. J Cell Biol 1994;125:825–842.

43. Stevens T, Esmon B, Schekman R. Early stages in the yeast secretory pathway are required for transport of carboxypeptidase Y to the vacuole. Cell 1982;30:439–448.

44. Conzelmann A, Riezman H, Desponds C, Bron C. A major 125-kd membrane glycoprotein of Saccharomyces cerevisiae is attached to the lipid bilayer through an inositol-containing phospholipid. EMBO J 1988;7:2233–2240.

45. Nuoffer C, Jeno P, Conzelmann A, Riezman H. Determinants for glycosylation anchoring of the Saccharomyces cerevisiae GAS1 protein to the plasma membrane. Mol Cell Biol 1991;11:27–37.

46. Nishizawa K, Freund C, Li J, Wagner G, Reinherz EL. Identification of a proline-binding motif regulating CD2-triggered T lymphocyte activation. Proc Natl Acad Sci U S A 1998;95:14897–14902.

47. Freund C, Dotsch V, Nishizawa K, Reinherz EL, Wagner G. The GYF domain is a novel structural fold that is involved in lymphoid signaling through proline-rich sequences. Nat Struct Biol 1999;6:656–660.

48. Schultz J, Milpetz F, Bork P, Ponting CP. SMART, a simple modular architecture research tool: identification of signaling domains. Proc Natl Acad Sci U S A 1998;95:5887–5894.

49. Letunic I, Copley RR, Schmidt S, Cai CH, Doerks T, Audit JR, Bork P. SMART 4.0: towards genomic data integration. Nucleic Acids Res 2004;32:D142–D144.

50. Nishizawa K, Freund C, Li J, Wagner G, Reinherz EL. Identification of a proline-binding motif regulating CD2-triggered T lymphocyte activation. Proc Natl Acad Sci U S A 1998;95:14897–14902.
51. Orlean P, Albright C, Robbins PW. Cloning and sequencing of the yeast gene for dolichol phosphate mannose synthase, an essential protein. J Biol Chem 1988;263:17499–17507.

52. Preuss D, Mulholland J, Kaiser CA, Orlean P, Albright C, Rose MD, Robbins PW, Botstein D. Structure of the yeast endoplasmic reticulum: localization of ER proteins using immunofluorescence and immunoelectron microscopy. Yeast 1991;7:891–911.

53. Rose MD, Misra LM, Vogel JP. KAR2, a karyogamy gene, is the yeast homolog of the mammalian BiP/GRP78 gene. Cell 1989;57:1211–1221.

54. Deshaies RJ, Schekman R. Structural and functional dissection of Sec62p, a membrane-bound component of the yeast endoplasmic reticulum protein import machinery. Mol Cell Biol 1990;10:6024–6035.

55. Allan BB, Moyer BD, Balch WE. Rab1 recruitment of p115 into a cis-SNARE complex: programming budding COPII vesicles for fusion. Science 2000;289:444–448.

56. Bi X, Corpina RA, Goldberg J. Structure of the Sec23/24-Sar1 pre-budding complex of the COPII vesicle coat. Nature 2002;419:271–277.

57. Miller EA, Liu Y, Barlowe C, Schekman R. ER-Golgi transport defects are associated with mutations in the Sed5p-binding domain of the COPII coat subunit, Sec24p. Mol Biol Cell 2005;16:3719–3726.

58. Fromont-Racine M, Rain JC, Legrain P. Toward a functional analysis of the yeast genome through exhaustive two-hybrid screens. Nat Genet 1997;16:277–282.

59. Kapetanovich L, Baughman C, Lee TH. Nm23H2 facilitates coat protein complex II assembly and endoplasmic reticulum export in mammalian cells. Mol Biol Cell 2005;16:835–848.

60. Palmer KJ, Konkel JE, Stephens DJ. PCTAIRE protein kinases interact directly with the COPII complex and modulate secretory cargo transport. J Cell Sci 2005;118:3839–3847.

61. Yamasaki A, Tani K, Yamamoto A, Kitamura N, Komada M. The Ca²⁺-binding protein ALG-2 is recruited to endoplasmic reticulum exit sites by Sec31A and stabilizes the localization of Sec31A. Mol Biol Cell 2006;17:4876–4887.

62. Shimizu W, Eizawa J, Nakamoto K, Uesaki S, Gabreski G, Aridor M, Yamamoto A, Nagahama M, Tagaya M, Tani K. p125 is localized in endoplasmic reticulum exit sites and involved in their organization. J Biol Chem 2005;280:10141–10148.

63. Kaiser C, Michaelis S, Mitchell A. Methods in Yeast Genetics. USA: Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York; 1994.

64. Christianson TW, Sikorski RS, Dante M, Shero JH, Hieter P. Multifunctional yeast high-copy-number shuttle vectors. Gene 1992;110:119–122.

65. Sikorski RS, Hieter P. A system of shuttle vectors and yeast host strains designed for efficient manipulation of DNA in Saccharomyces cerevisiae. Genetics 1989;122:19–27.

66. Yahara N, Ueda T, Sato K, Nakano A. Multiple roles of Arf1 GTPase in the yeast exocytic and endocytic pathways. Mol Cell Biol 2001;12:221–238.

67. Sato M, Sato K, Nishikawa S, Hirata A, Kato J, Nakano A. The yeast RER2 gene, identified by endoplasmic reticulum protein localization mutations, encodes cis-prenyltransferase, a key enzyme in dolichol synthesis. Mol Cell Biol 1999;19:471–483.

68. Rothblatt J, Schekman R. A hitchhiker’s guide to analysis of the secretory pathway in yeast. Methods Cell Biol 1989;32:3–36.

69. Nishikawa S, Nakano A. The GTP-binding Sar1 protein is localized to the early compartment of the yeast secretory pathway. Biochim Biophys Acta 1991;1093:135–143.

70. Sato K, Nakano A. Emp47p and its close homolog Emp48p have a tyrosine-containing endoplasmic reticulum exit signal and function in glycoprotein secretion in Saccharomyces cerevisiae. Mol Biol Cell 2002;13:2518–2532.

71. Wuestehube LJ, Schekman RW. Reconstitution of transport from endoplasmic reticulum to Golgi complex using endoplasmic reticulum-enriched membrane fraction from yeast. Methods Enzymol 1992;219:219–236.

72. Kyte J, Doolittle RF. A simple method for displaying the hydropathic character of a protein. J Mol Biol 1982;157:105–132.

73. Yamanushi T, Hirata A, Oka T, Nakano A. Characterization of yeast sar1 temperature-sensitive mutants, which are defective in protein transport from the endoplasmic reticulum. J Biochem (Tokyo) 1996;120:452–458.